Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 1

1(16.7%)

Phase 3

1(16.7%)

6Total

N/A(4)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02009462Phase 1Completed

Artefill for the Treatment of HIV-associated Facial Lipoatrophy

Role: collaborator

NCT02642627Not ApplicableCompleted

The Use of Bellafill for Atrophic Acne Scar Correction in the Full Facial Area

Role: lead

NCT01559922Phase 3Completed

Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction

Role: lead

NCT02643628Not ApplicableCompleted

A Pilot Study to Evaluate the Safety and Effectiveness of Microneedling and Bellafill to Treat Facial Acne Scars

Role: lead

NCT03299712Not ApplicableCompleted

Protocol for the Post-approval Study of Artefill for Correction of Nasolabial Folds

Role: lead

NCT00778089Not ApplicableTerminated

Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing

Role: lead

NCT03327311Completed

Histological Analysis of Bellafill Injected Tissue at Various Time Points

Role: lead

All 7 trials loaded